Member Info for Laura2022

Biggest cost cutting would be sacking useless Lenigas and Bell taking a pay freeze

Staffing costs are astronomical over last5yrs

Literally a gravy train

While the directors consider the Company to be currently solvent, should the above measures prove insufficient to meet the Company's financial obligations, then, as noted in the Interim Statement, the Company may be unable to continue trading and would have to file for Administration

Helpful

All the lithium and gold charts won't help

RRR Is dead and insolvent

The Company announces that Chris Goulden, Chief Financial Officer of Corero, has purchased 220,264 Ordinary Shares. Following this purchase, Chris Goulden has a total beneficial interest in 360,887 Ordinary Shares equivalent to 0.07% per cent. of the Company's issued share capital.

This should allay the market perception when confirmed

Corero's cash balance as at 30 June 2025 was $3.1 million (H1 2024: $7.9 million) and the Group has no outstanding debt. Like revenue, the change in mix toward DDPaaS has increased the amount of cash receipts deferred into future periods. The Group is in advanced discussions with its banking partner to put in place an overdraft facility to manage the increased working capital requirements of the business 

Amd directors buys

Bought a few today

He Company's convertible and debt holders have been strongly supportive of the Company, and we are discussing with the loan note holders the terms of an extension to the Convertible Loan Notes. A failure to generate sufficient funds by disposals or external funding might put in question the Company's ability to continue operations."

In broad terms, this remains the Company's financial position with no material changes, and the Company believes that it continues to enjoy the support of key shareholders and certain creditors.

Since then, despite credible assurances that the DRC judgment has now been rendered, the Company still awaits a copy, although it remains of the view that this is imminent. Until this judgement is publicised and the Company receives a copy, it is unable to pursue its arbitration award as explained above.

Winterflood Retail Access Platform (the "WRAP"), will be conducted at a price of 0.5 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents a discount of 42.9 per cent. to Verici Dx's closing mid-price on 18 July 2025 (being the

Ive been watching for 6mths and posted a few times as thus

Most recently a few weeks before results

Something still seems "not as it seems" but of things turned our to be not as bad as feared by tje market then GRL becomes very cheap

We aw already nearly 1mth into H1

adoption programme and the pipeline of global enterprises is considerable and growing in several key geographies. Eagle Eye's product development to support this OEM continues at pace, with all milestones achieved to date. The Board continues to expect the first contracts to be signed in H1 FY26,

Jester

They also anticipate the major signature on large contracts soon

With this already booked and now with the biostatistics division winning its inaugural contracts last month it is feasible that a £1mln-1.5mln+ year is possible for 2025/26

"The Company started the current financial year ending 30 June 2026 (FY26) with approx. £593k(*) of contracted revenue that is projected to be recognised within the year."

* this is a near 20% increase on same time last July

As you say 2phevs

This could be a very obvious fit with PYC

"We are the exclusive Clinical Decision Support Partner for the National Health Service (NHS) Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies."

Thanks Trench/2lhevs

And ANIC

Sorry

CNR

He did same on CGNR

Stiching up long term holders

Burt

Afternoon

All trades 0 479/48/49/50+ are buys

As you say..no stock

Eg £5k is 0 54

Clearly cannot see what the company is building and has won more contracts than 3 -3 other bio techs put together and whom are nowhere near breakeven revenues NOT with the client diversity, or new client wins nor with 3 -4 strings to the bow ( consultancy, bio statistic, personalised medicine, dosing software)

16th July - new contract with partner Numab

14th July - Trading statement

ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46%

10th July : integration of PYC platform into global personalosed medical provoder DoseMeRx

1st July - new contract

16th June x 2 biostatistics contracts (first ones from new division)

29th May RNSPhysiomics Awarded Contract Extension

9th May RNSContract Award with New UK Client

17th Apr Physiomics Awarded New Contract

16th Apr RNS-R Publication of Peer Reviewed Article

15th Apr new contract

17th Mar RNS Contract Award with new client

Moving up